盤中異動 | 藥明生物盤中下跌5%,報於98.0港元
2021年12月6日10時8分,藥明生物(HK02269)盤中下跌5%,報於98.0港元,成交額達5.59億港元,換手率達到0.12%。
11月23日訊,藥明生物(02269)公佈,於2021年11月23日,其已根據受限制股份獎勵計劃批準授出合共約394.46萬股受限制股份予集團486名僱員,惟須待受限制股份獎勵計劃承授人接納。公告顯示,公司將向受限制股份獎勵計劃受託人發行及配發的新股份相當於本公告日期公司於發行及配發後經擴大已發行股本的約0.09%。此外,於2021年11月23日,其已根據全球合夥人股份獎勵計劃批準授出合共約272.38萬股受限制股份予集團198名僱員(統稱爲“全球合夥人計劃承授人”)。公司將向全球合夥人計劃受託人發行及配發的新股份,相當於本公告日期該公司於發行及配發後經擴大已發行股本的約0.06%。
11月9日,中金:醫藥股已具備配置價值,看好藥明生物(02269)、信達生物(01801)等。11月8日,瑞信:維持藥明生物(02269)“跑贏大市”評級,目標價151港元。11月5日,中泰國際:上調藥明生物(02269)目標價至143.7港元,評級升至“買入”。
最新的財務數據顯示,公司於2021年2季度,營業收入44.07億人民幣,淨利潤18.83億人民幣;營業收入同比增加126.67%,毛利潤同比增加190.8%,淨利潤同比增加157.67%。
盈立趨勢長盈模型最近一次交易信號,2021年11月23日出現觀望信號,觸發價格爲101.3港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.